MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajp.2026.104979

Медицинская библиотека · Asian journal of psychiatry · 2026

Adjunctive pimavanserin in schizophrenia: A systematic review and meta-analysis with a focus on negative-symptom programmes.

Dos Santos Pereira Samuel Izaias, de Oliveira Isabela Borja, Ferreira Matheus Hissa Lourenço, Mert Alper, de Lima Prado Marcelo Lucas, Lyra Gabriel Oliveira Teixeira, de Araújo Julia Costa, Xavier Débora, de Aguiar Débora Regina, Sherpa Nima Norbu

Систематический обзорСтатьяМетаанализПеревод в очереди

Аннотация

Negative symptoms of schizophrenia are a major determinant of functional disability and remain a persistent unmet therapeutic need. Pimavanserin (NbN: serotonin 5-HT₂A receptor inverse agonist/antagonist) has been investigated as an adjunctive treatment for negative symptoms, but clinical evidence remains inconsistent. We conducted a systematic review and meta-analysis to evaluate the efficacy, safety, and tolerability of adjunctive pimavanserin in adults with schizophrenia. PubMed, Web of Science, Cochrane CENTRAL, Scopus, Ovid, Europe PMC, ClinicalTrials.gov, and the WHO ICTRP were searched from inception through August 2025. Randomized controlled trials comparing adjunctive pimavanserin with placebo were included. Random-effects meta-analyses were performed, and treatment effects were interpreted in relation to established minimal clinically important differences (MCIDs). Risk of bias was assessed using Cochrane RoB 2, and certainty of evidence was evaluated with GRADE. Four randomized controlled trials including 1676 randomized participants were identified, encompassing heterogeneous populations (acute exacerbation, inadequate response, and predominant negative symptoms). No clinically meaningful benefit was observed on the primary negative symptom endpoint used in predominant negative symptom studies (NSA-16). Small statistically significant reductions were observed for PANSS total and PANSS negative scores, but effect sizes remained well below MCID thresholds. No significant benefits were observed for other symptom domains or global outcomes. Pimavanserin was generally well tolerated, with no increased risk of serious adverse events or treatment discontinuation versus placebo. Overall, adjunctive pimavanserin demonstrates statistically detectable but clinically modest effects that do not support routine clinical use for negative symptoms of schizophrenia.

Для цитирования: Dos Santos Pereira Samuel Izaias, de Oliveira Isabela Borja, Ferreira Matheus Hissa Lourenço, Mert Alper, de Lima Prado Marcelo Lucas, Lyra Gabriel Oliveira Teixeira, de Araújo Julia Costa, Xavier Débora, de Aguiar Débora Regina, Sherpa Nima Norbu. Adjunctive pimavanserin in schizophrenia: A systematic review and meta-analysis with a focus on negative-symptom programmes.. Asian journal of psychiatry. 2026. DOI: 10.1016/j.ajp.2026.104979.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.